iPS Bio, Inc., a Korean company developing cell therapy and drug discovery platforms based on induced pluripotent stem cell (iPSC) technology, has established a Japanese subsidiary in Yokohama City.
iPS Bio is a Korea-based biotech company developing cell therapy and drug discovery platforms using induced pluripotent stem cell (iPSC) technology, with a focus on treating intractable neurodegenerative diseases such as Huntington’s disease.
In 2022, the company became the first overseas recipient of clinical-grade iPSC stock from the CiRA Foundation of Kyoto University. It is conducting clinical trials using GMP-grade iPSC products for indications including Huntington’s disease, stroke, Alzheimer’s disease, and immune-oncology.
In 2024, iPS Bio joined Shonan Health Innovation Park to promote collaboration with Japanese pharmaceutical and biotech companies.
Building on these efforts, the company established its Japanese subsidiary, iPS Bio Japan Co., Ltd., in Yokohama City, Kanagawa Prefecture in December 2025 to strengthen its development activities in Japan.
Global Gateway Advisors, we are the preferred partner in assisting companies from all over Asia in their expansion into Japan market.
https://www.global-gw.com
Source: https://www.jetro.go.jp/en/invest/newsroom/2026/67ae56c2e72ba38c.html
